
Tetrahedron Letters, Vol.24, No.5, pp 477-480, 1983 0040-4039/83/050477-04\$03.00/0 Printed in Great Britain ©1983 Pergamon Press Ltd.

## AZAPROSTANOIDS II. SYNTHESIS OF 12-AZACARBOPROSTACYCLIN ANALOGS1

Chia-Lin J. Wang Central Research and Development Department, Experimental Station E. I. du Pont de Nemours and Company Wilmington, Delaware 19898


ABSTRACT: A total synthesis of 12-azacarboprostacyclin analogs  $\underline{1}$  and  $\underline{2}$  from 9 is described.


Synthetic orally active drugs based on  $\operatorname{prostacyclin}^2$  (PGI<sub>2</sub>) could be potentially useful in the treatment of thrombotic disease, hypertension, platelet consumption and all forms of vascular disease.<sup>3</sup> Tremendous efforts have been focused upon carboprostacyclin<sup>4</sup> because of its PGI<sub>2</sub>-like biological profile.<sup>5</sup> We have been interested in preparing azacarboprostacyclin analogs as potential anti-thrombotic agents for some time. A recent report<sup>6</sup> describing the synthesis of 12-azaprostacyclin analogs prompts us to disclose our efforts in this area. In this communication, we wish to report the synthesis of 12-azacarboprostacyclin analogs <u>1</u> and <u>2</u> from a common intermediate <u>9</u>.



<u>1</u>,  $R = R^1 = R^2 = H$ <u>2</u>, R = Me,  $R^1$ ,  $R^2 = O$ 


Retrosynthetically,  $\underline{1}$  might be derived from  $\underline{3}$  by a Wittig reaction. Compound  $\underline{3}$  should be easily synthesized from  $\underline{4}$  which, in turn, might be obtained by Dieckmann cyclization of  $\underline{5}$  followed by decarboxylation. The readily available  $\underline{6}^7$  could be a suitable starting material for compound  $\underline{5}$ . The synthesis of 2 was also realized via the common intermediate  $\underline{9}$ .






The actual synthetic route leading to 1 is shown in Scheme I. Compound 6 was reacted with the phosphonate derived from trimethyl phosphonoacetate to give the  $\alpha,\beta$ -unsaturated ester which was smoothly hydrogenated to the diester 7 as an oil in 70% yield after HPLC purification [IR (neat) 1740, 1700  $cm^{-1}$ ; NMR (CDCl<sub>3</sub>) δ 4.17 (q, J=7Hz, 2CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 3.70 (S, CO<sub>2</sub>CH<sub>3</sub>), 1.27 (t, J=7Hz,  $2CO_2CH_2CH_2)$ ]. Dieckmann cyclization of 7 followed by decarboxylation<sup>8</sup> gave rise to the oily ketone 8 in 51% yield after purification by HPLC [IR(CH2C12) 1750, 1700 cm<sup>-1</sup>; NMR (CDCl<sub>3</sub>)  $\delta$  4.11 (q, J=7Hz, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 1.23 (t, J=7Hz, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>)] Ketone 8 was then converted to 9 in 57% yield by the following transformations: 1. protection of the ketone as dimethyl ketal; 2. cleavage of the carbamate by methyl lithium; 3. conjugate addition of the resulting amine to 3-keto-1-heptene and finally, reduction of the ketone. The protected ketone in 9 was unmasked to give 3 as an oil after HPLC purification [IR ( $CH_2Cl_2$ ) 3250, 1740 cm<sup>-1</sup>]. Compound 3 was allowed to react with the phosphorane derived from (4-carboxybuty1)triphenylphosphonium bromide to yield 19 in 85% yield after purification by flash column chromatography using methanol-methylene chloride as an eluent.


## Scheme I






Conditions: a. (MeO) 2<sup>PCH</sup>2<sup>CO</sup>2<sup>Me</sup>/NaH/THF; b. H<sub>2</sub>/10%Pd on C/EtOAc; c. NaH/DMF; d. NaCl/DMSO-H<sub>2</sub>O/150°; e. CH(OMe) 3/P-TSOH/MeOH-CH<sub>2</sub>Cl<sub>2</sub>; f. MeLi/THF/0°; g. //glyme; h. NaBH<sub>4</sub>/EtOH/-20°; i. p-TSOH/acetone; j. Ph<sub>3</sub><sup>P</sup>(CH<sub>2</sub>) 4 CO<sub>2</sub>HBF/KOBu<sup>t</sup>/ PhH/80°

In order to synthesize 2 by using an intermediate in Scheme I, it requires conversion of the pyrrolidine ring to a five-membered lactam. After several unsuccessful attempts on  $\underline{3}$  and  $\underline{1}$ , we turned our attention to compound The hydroxy group in  $\underline{9}$  was protected as an acetate to afford 9 (Scheme II). <u>10</u> [mp 82-84°C;  $IR(CH_2Cl_2)$  1730 cm<sup>-1</sup>; NMR (CDCl<sub>3</sub>)  $\delta$  3.24 (s, OCH<sub>3</sub>), 3.16 (s, OCH<sub>3</sub>), 2.00 (s, OCCH<sub>3</sub>)]. Oxidation of <u>10</u> to lactam <u>11</u> was realized by employing N-bromosuccinimide (NBS).<sup>10</sup> Compound 11 was easily isolated from the other unidentified products, albeit in 30% yield [IR ( $CH_2Cl_2$ ) 1725, 1670 cm<sup>-1</sup>; NMR  $(CDC1_3)$   $\delta$  3.10 (s, 2 OCH<sub>3</sub>), 2.00 (s, OCH<sub>3</sub>)]. In a small scale (0.15 mM) NBS oxidation, only desired 11, which showed normal five-membered lactam absorption<sup>1</sup> in IR, was observed. However, the other regioisomer 12 [IR (CH<sub>2</sub>Cl<sub>2</sub>) 1730 and 1635 cm<sup>-1</sup>] appeared when attempting to scale-up the reaction. With <u>11</u> in hand, the remaining steps were straightforward. Deprotection of the acetate and dimethyl ketal afforded the hydroxyketone 13 [IR(CH<sub>2</sub>Cl<sub>2</sub>) 3460, 1750, 1670 cm<sup>-1</sup>] Compound 13, upon treatment with the phosphorane described previously, gave an acid<sup>12</sup> which was converted to  $2^9$ . The overall yield from <u>11</u> to <u>2</u> was <u>ca</u> 30%.





While compound <u>1</u> did not inhibit cat platelet aggregation induced by arachidonic acid<sup>13</sup>, compound <u>2</u> gave 25% inhibition of ADP-induced rat platelet aggregation at  $2.5 \times 10^{-4}$  M.<sup>14</sup>

## References and Notes

- Contribution No. 3136 from Central Research and Development Department. For Azaprostanoids I. see C.-L. J. Wang, <u>Tetrahedron Lett.</u>, <u>23</u>, 1067 (1982).
- 2. S. Moncada, R. Gryglewski, S. Bunting and J.R. Vane, Nature, 263, 663 (1976)
- 3. J.R. Vane and S. Bergstrom, ed., "Prostacyclin", New York, Raven Press, 1979.
- 4. For recent publications on the synthesis of carboprostacyclin, see (a) Y. Konishi, M. Kawamura, Y. Iguchi, Y. Arai and M. Hayashi, Tetrahedron, <u>37</u>, 43 (1981); (b) M. Yamazaki, M. Shibasaki and S. Ikegami, <u>Chem. Lett.</u>, 1245 (1981); (c) P.A. Aristoff, <u>J. Org. Chem.</u>, <u>46</u>, 1954 (1981) and references therein.
- 5. (a) B.J.R. Whittle, S. Moncada, F. Whiting and J.R. Vane, <u>Prostaglandins</u>, 605 (1980); (b) J.W. Aiken, R. J. Shebuski, <u>ibid</u>, <u>19</u>, 629 (1980).
- 6. F. Cassidy, R.W. Moore, G. Wootton, K.H. Baggaley, G.R. Geen, L.J.A. Jennings and A.W.R. Tyrrell, Tetrahedron Lett., <u>22</u>, 253 (1981).
- 7. (a) T.A. Geissman and A.C. Waiss, Jr., <u>J. Org. Chem.</u>, <u>27</u>, 139 (1962); (b)
  G. Stork and A. G. Schultz, <u>J. Am. Chem. Soc.</u>, <u>93</u>, 4074 (1971).
- 8. A.P. Krapcho and A.J. Lovey, <u>Tetrahedron Lett.</u>, 957 (1973).
- 9. 1: oil, IR  $(CH_2Cl_2)$  3400-2600 (br), 1720 cm<sup>-1</sup>; NMR  $(CDCl_3)$   $\delta$  6.50 (bs, 2H,  $-CO_2H \& OH$ ), 5.11 (m,1H), 4.20-1.00 (m, 29H), 0.83 (t,3H); HRMS m/z 337.2611 (M+), calcd. for  $C_{20}H_{35}NO_3$ : 337.2617.

<u>2</u>: oil, consisting of four racemic diastereomers, IR  $(CH_2Cl_2)$  3610-3300 (br), 1740, 1665 cm<sup>-1</sup>; NMR  $(CDCl_3)$  & 5.20 (m, 1H), 3.63 (S, 3H), 4.10-1.00 (m, 27H), 0.90 (t, 3H); HRMS m/z 365.2559 (M<sup>+</sup>), calcd. for  $C_{21}H_{35}NO_4$ : 365.2566.

- 10. A. Picot and X. Lusinchi, Synthesis, 109 (1975).
- ll. In Ref. 6, a closely related five-membered lactam has shown IR absorption at 1670  $\rm cm^{-1}$ .
- 12. This acid could not be separated from the Wittig reagent.
- 13. The author thanks Professor A. M. Lefer of Thomas Jefferson University for conducting the tests.
- 14. I am indebted to Dr. W. Galbraith (Biochemicals Department) for obtaining the data. Technical assistance from Ms. T.L. Taylor is greatly appreciated.

(Received in USA 7 October 1982)